OCD Therapy

Obsessive-Compulsive Disorder (OCD) therapy encompasses a range of evidence-based treatment approaches designed to reduce the severity and impact of obsessive thoughts and compulsive behaviors that characterize this debilitating anxiety disorder. Cognitive-behavioral therapy, particularly exposure and response prevention (ERP), stands as the gold-standard psychotherapeutic intervention, demonstrating robust efficacy across diverse clinical populations. Contemporary treatment paradigms integrate pharmacological interventions, primarily selective serotonin reuptake inhibitors (SSRIs), with structured psychotherapy to optimize therapeutic outcomes. Advanced therapeutic modalities including acceptance and commitment therapy (ACT), inference-based cognitive-behavioral therapy (I-CBT), and intensive outpatient programs have expanded the treatment landscape, offering alternatives for individuals who do not respond adequately to first-line interventions. This article examines the theoretical foundations, empirical evidence, clinical applications, and emerging directions in OCD therapy, providing mental health professionals with a comprehensive understanding of current best practices in treating this complex disorder.

Understanding Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder represents a chronic psychiatric condition characterized by intrusive, unwanted thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) performed to reduce anxiety or prevent perceived harm. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) classifies OCD as a distinct diagnostic category separate from anxiety disorders, reflecting advances in understanding its unique neurobiological and phenomenological features (American Psychiatric Association, 2022). The disorder affects approximately 2-3% of the global population across the lifespan, with onset typically occurring in childhood, adolescence, or early adulthood.

The phenomenology of OCD varies considerably across individuals, with obsessions commonly focusing on contamination fears, symmetry and ordering concerns, forbidden or taboo thoughts (aggressive, sexual, or religious in nature), and fears of harm to self or others. Compulsions correspondingly manifest as washing and cleaning rituals, checking behaviors, counting, arranging, and mental rituals such as prayer or silent repetition of words. The heterogeneity of symptom presentations has led researchers to identify distinct symptom dimensions that may respond differentially to specific therapeutic interventions (Bloch et al., 2008). Understanding this complexity proves essential for treatment planning and predicting therapeutic response.

Theoretical Foundations of OCD Therapy

The cognitive-behavioral model of OCD, articulated comprehensively by Salkovskis (1985), posits that obsessive thoughts represent normal intrusive cognitions that become problematic through catastrophic misinterpretation and maladaptive responses. According to this framework, individuals with OCD assign excessive importance to intrusive thoughts, interpreting them as indicators of danger, responsibility, or moral transgression. This cognitive appraisal triggers anxiety and distress, prompting compulsive behaviors designed to neutralize the perceived threat or prevent anticipated catastrophe. Unfortunately, while compulsions provide temporary anxiety relief, they maintain the disorder by preventing disconfirmation of catastrophic beliefs and reinforcing the perceived necessity of ritualistic behavior.

Building upon behavioral principles established by Mowrer’s two-factor theory, OCD is conceptualized as maintained through both classical and operant conditioning processes. Neutral stimuli become associated with anxiety through classical conditioning, while compulsive behaviors are negatively reinforced through anxiety reduction, strengthening the response pattern. This theoretical understanding directly informs exposure and response prevention therapy, which systematically disrupts these maintaining mechanisms. Contemporary cognitive models have been further refined to incorporate metacognitive factors, thought-action fusion, inflated responsibility beliefs, and intolerance of uncertainty as central maintaining factors requiring therapeutic attention (Obsessive Compulsive Cognitions Working Group, 2005).

Exposure and Response Prevention: The Gold Standard

Exposure and response prevention remains the most extensively researched and empirically validated psychotherapeutic intervention for OCD, with efficacy established through numerous randomized controlled trials and meta-analyses. ERP operates by systematically exposing individuals to anxiety-provoking obsessional triggers while preventing the performance of compulsive responses, thereby facilitating habituation to anxiety and extinction of the conditioned fear response. Foa and colleagues developed the comprehensive treatment protocol that has become standard practice, typically delivered across 12-20 weekly sessions with substantial between-session homework assignments (Foa et al., 2005).

The ERP protocol begins with psychoeducation about OCD and the treatment rationale, followed by collaborative development of an exposure hierarchy ranking feared situations from least to most anxiety-provoking. Exposures proceed systematically through this hierarchy, with patients confronting increasingly challenging triggers while refraining from compulsions, safety behaviors, and mental neutralization strategies. In-session exposures typically last 60-90 minutes or until anxiety demonstrates clear reduction, with patients recording subjective units of distress (SUDs) ratings throughout the exposure to track habituation patterns. The therapist’s role encompasses providing structure, encouragement, and behavioral coaching while carefully avoiding reassurance that would undermine the exposure’s therapeutic potential.

Research demonstrates that ERP produces clinically significant improvement in 60-75% of individuals who complete treatment, with effect sizes typically ranging from large to very large. A landmark meta-analysis by Olatunji and colleagues (2013) examining 13 randomized controlled trials found a mean between-group effect size of 1.31 favoring ERP over control conditions, with gains maintained at follow-up assessments extending to one year post-treatment. Patient factors associated with positive treatment response include higher baseline insight, greater treatment motivation, completion of homework assignments, and lower baseline depression severity. Conversely, comorbid conditions including severe depression, personality disorders, and substance use disorders may complicate treatment and necessitate modified or integrated approaches.

ERP Treatment Phase	Key Components	Typical Duration
Assessment & Psychoeducation	Diagnostic evaluation, symptom mapping, treatment rationale	2-3 sessions
Hierarchy Development	Collaborative identification and ranking of feared situations	1-2 sessions
Graduated Exposure	Systematic confrontation with triggers, response prevention	8-15 sessions
Relapse Prevention	Consolidation of gains, identification of warning signs, maintenance planning	2-3 sessions

Cognitive Therapy Approaches

While behavioral interventions targeting compulsions form the cornerstone of OCD treatment, cognitive therapy approaches focus on modifying the maladaptive beliefs and appraisals that maintain obsessional distress. Wilhelm and Steketee (2006) developed a comprehensive cognitive therapy protocol that systematically addresses inflated responsibility beliefs, thought-action fusion, overestimation of threat, intolerance of uncertainty, perfectionism, and need for control. This approach employs standard cognitive restructuring techniques including Socratic questioning, behavioral experiments, continuum techniques, and examination of evidence to challenge distorted cognitions without requiring direct exposure to feared stimuli.

Inference-based cognitive-behavioral therapy represents an alternative cognitive approach developed specifically for OCD by O’Connor and colleagues. I-CBT conceptualizes obsessions as originating from inferential confusion—the tendency to trust imagined possibilities more than sensory reality. Treatment focuses on helping patients recognize when they shift from reality-based processing to imaginative doubt, strengthening trust in their senses, and developing metacognitive awareness of the inferential processes generating obsessional concerns (O’Connor et al., 2005). Preliminary research suggests I-CBT may prove particularly beneficial for individuals with poor insight or those who struggle with traditional exposure-based approaches.

Comparative studies examining cognitive therapy alone versus ERP have generally demonstrated slightly superior outcomes for ERP or combined approaches, though cognitive interventions produce meaningful benefits for many patients. A meta-analysis by Rosa-Alcázar and colleagues (2008) found cognitive therapy generated moderate to large effect sizes, with combined cognitive-behavioral protocols potentially offering advantages over either approach in isolation. Contemporary practice typically integrates cognitive and behavioral components, recognizing that cognitive restructuring may enhance motivation for exposure exercises while behavioral experiments provide powerful disconfirmation of dysfunctional beliefs.

Pharmacological Interventions

Selective serotonin reuptake inhibitors constitute the first-line pharmacological treatment for OCD, with robust evidence supporting their efficacy in reducing symptom severity. Medications demonstrating established efficacy include fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram, typically requiring higher doses than those employed for depression treatment. The serotonin-norepinephrine reuptake inhibitor venlafaxine and the tricyclic antidepressant clomipramine also demonstrate significant anti-obsessional properties, with clomipramine showing superior efficacy in some comparative trials despite less favorable side effect profiles (Soomro et al., 2008).

Pharmacotherapy typically requires 10-12 weeks at therapeutic doses to achieve maximum benefit, with gradual dose titration minimizing adverse effects and improving tolerability. Response rates to SSRI monotherapy approximate 40-60%, with patients experiencing average symptom reductions of 20-40% on standardized measures. Meta-analytic evidence indicates medication produces moderate effect sizes, generally smaller than those associated with ERP but still clinically meaningful. The combination of medication and cognitive-behavioral therapy may offer advantages over either treatment alone, particularly for individuals with severe symptoms, comorbid depression, or incomplete response to monotherapy (Simpson et al., 2008).

For individuals demonstrating inadequate response to first-line pharmacological interventions, augmentation strategies have received empirical support. Low-dose antipsychotic medications, particularly risperidone, aripiprazole, and quetiapine, show modest efficacy when added to ongoing SSRI treatment, especially for patients with comorbid tic disorders or poor insight. Other augmentation approaches including N-acetylcysteine, memantine, and lamotrigine have shown promise in preliminary studies but require further investigation. Treatment-resistant cases may warrant consultation with specialized OCD programs offering intensive treatment, medication algorithm optimization, or consideration of neurosurgical interventions such as deep brain stimulation for the most severe, refractory presentations.

Acceptance and Commitment Therapy

Acceptance and Commitment Therapy has emerged as a third-wave cognitive-behavioral approach showing considerable promise for OCD treatment. Rather than focusing on symptom reduction through habituation or cognitive change, ACT emphasizes psychological flexibility—the ability to remain present with uncomfortable internal experiences while pursuing valued life directions. For OCD specifically, ACT interventions target experiential avoidance, teaching patients to observe obsessive thoughts non-judgmentally without attempting to suppress, neutralize, or control them (Twohig et al., 2010).

The ACT protocol for OCD incorporates six core processes: acceptance of uncomfortable thoughts and feelings, cognitive defusion from literal meaning of obsessions, present-moment awareness, self-as-context rather than self-as-content, clarification of personal values, and committed action toward value-consistent behavior despite obsessional discomfort. Treatment exercises may include mindfulness meditation, metaphor work, values clarification activities, and behavioral commitment exercises that resemble exposure but are framed as pursuing valued living rather than anxiety reduction. This subtle but important distinction may reduce treatment dropout and enhance motivation for individuals ambivalent about traditional exposure therapy.

Research examining ACT for OCD has demonstrated encouraging outcomes, with effect sizes comparable to traditional cognitive-behavioral approaches. Twohig and colleagues (2018) conducted a randomized controlled trial comparing ACT to progressive relaxation training, finding large within-group effect sizes for ACT (d = 2.17) with 46% of participants achieving clinically significant improvement. Another investigation comparing ACT to ERP found equivalent outcomes at post-treatment and follow-up, suggesting ACT may represent a viable alternative for patients who prefer acceptance-based approaches or have not responded to traditional interventions. Additional research is needed to identify patient characteristics predicting differential response to ACT versus ERP.

Specialized Treatment Modalities

Intensive and residential treatment programs have proliferated in recent years to address the needs of individuals with severe OCD who require more comprehensive intervention than traditional outpatient therapy provides. These programs typically offer 30-40 hours per week of structured treatment including multiple daily exposure sessions, group therapy, family involvement, and psychiatric management. Intensive programs demonstrate substantial efficacy, with research by Oldfield and colleagues (2011) showing mean Yale-Brown Obsessive Compulsive Scale (Y-BOCS) reductions of 50-60% following intensive treatment, with gains maintained at follow-up.

Family-based treatment for pediatric OCD recognizes the developmental context of childhood-onset disorder and the crucial role family members play in accommodation and maintenance of symptoms. Family accommodation—participation in rituals, providing reassurance, or modifying household routines to reduce patient distress—occurs in approximately 90% of families but maintains symptoms and predicts poorer treatment outcomes. Family-based cognitive-behavioral therapy helps parents recognize and reduce accommodation while supporting their child’s exposure exercises, teaching effective communication strategies, and addressing family dysfunction that may complicate recovery (Piacentini et al., 2011). This approach has demonstrated superior outcomes compared to individual child therapy for many pediatric cases.

Group cognitive-behavioral therapy represents a cost-effective treatment delivery format that offers additional therapeutic benefits through peer support, normalization of experiences, and opportunities for vicarious learning. While individual therapy remains the preferred format for many patients, particularly those with severe symptoms or comorbid conditions, group treatment produces clinically meaningful improvements with effect sizes approaching those of individual therapy. Group formats work particularly well for individuals with similar symptom presentations, such as contamination fears or harm obsessions, allowing for collaborative exposure exercises and shared problem-solving.

Technological Innovations in Treatment Delivery

Internet-delivered cognitive-behavioral therapy has emerged as an accessible treatment option addressing the significant barriers many individuals face in accessing specialized OCD care. Several web-based platforms offer structured programs incorporating psychoeducation, exposure hierarchies, symptom tracking, and therapist guidance through asynchronous messaging or videoconferencing. Research by Andersson and colleagues (2012) demonstrated that internet-delivered CBT produces moderate to large effect sizes comparable to face-to-face treatment for many patients, with particularly strong outcomes when therapist support accompanies self-directed exercises.

Virtual reality exposure therapy represents an innovative technological advancement allowing for immersive, controlled exposure experiences that may be impractical or impossible to arrange in vivo. VR applications have been developed for contamination fears, harm obsessions, and symmetry concerns, enabling repeated exposure trials in safe, graduated progressions. While research remains limited, preliminary studies suggest VR exposure produces outcomes comparable to traditional exposure methods with high patient acceptability and engagement. The technology may prove particularly valuable for individuals with poor imaginative capacity or those requiring extensive therapist-assisted exposures that would be logistically challenging in natural environments (Kim et al., 2008).

Mobile health applications offer additional tools for extending therapeutic contact between sessions, facilitating symptom monitoring, and delivering just-in-time interventions during moments of elevated distress. Apps designed for OCD typically include features such as exposure logging, anxiety tracking, mindfulness exercises, therapist messaging capabilities, and psychoeducational resources. While these technologies show promise for augmenting traditional treatment and supporting maintenance of gains, research examining their independent efficacy and optimal integration with therapist-delivered interventions remains nascent. Clinicians should carefully evaluate apps for evidence-based content and appropriate security protections before recommending them to patients.

Assessment and Treatment Planning

Comprehensive assessment forms the foundation of effective OCD treatment, requiring careful differential diagnosis, symptom characterization, and identification of maintaining factors. The Yale-Brown Obsessive Compulsive Scale remains the gold-standard clinician-administered measure, assessing time occupied by obsessions and compulsions, interference with functioning, distress, resistance, and control across both symptom domains. The Y-BOCS demonstrates excellent psychometric properties and sensitivity to treatment effects, making it the primary outcome measure in most clinical trials (Goodman et al., 1989). Self-report instruments including the Obsessive-Compulsive Inventory-Revised and the Dimensional Obsessive-Compulsive Scale provide additional perspectives on symptom severity and dimensional presentations.

Functional assessment identifies the specific triggers, cognitive appraisals, emotional responses, and behavioral consequences maintaining each patient’s unique symptom presentation. This idiographic analysis informs individualized treatment planning, exposure hierarchy development, and identification of cognitive targets for restructuring. Detailed assessment of safety behaviors, mental rituals, and subtle compulsions proves essential, as these covert responses frequently escape initial detection but significantly impair treatment progress when unaddressed. Assessment must also evaluate comorbid conditions including depression, other anxiety disorders, attention-deficit/hyperactivity disorder, autism spectrum disorder, and personality pathology that may require concurrent treatment or modified therapeutic approaches.

Treatment planning decisions consider symptom severity, patient preferences, treatment availability, comorbidity profile, and prior treatment history. Practice guidelines from the American Psychological Association recommend cognitive-behavioral therapy, specifically ERP, as the first-line psychosocial intervention for OCD, with combined medication and psychotherapy considered for moderate to severe presentations or when either treatment alone proves insufficient (American Psychological Association, 2007). Individuals with very severe symptoms, substantial functional impairment, or high suicide risk may require intensive treatment programs or inpatient stabilization before transitioning to outpatient care. Shared decision-making that respects patient autonomy while providing expert guidance optimizes treatment engagement and outcomes.

Assessment Instrument	Type	Subscales	Administration Time
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)	Clinician-rated	Obsessions severity, Compulsions severity	20-30 minutes
Obsessive-Compulsive Inventory-Revised (OCI-R)	Self-report	Washing, Checking, Ordering, Obsessing, Hoarding, Neutralizing	5-10 minutes
Dimensional Obsessive-Compulsive Scale (DOCS)	Self-report	Contamination, Responsibility for harm, Unacceptable thoughts, Symmetry	10-15 minutes
Depression Anxiety Stress Scales (DASS-21)	Self-report	Depression, Anxiety, Stress	5-10 minutes

Cultural Considerations and Diversity

Cultural context significantly influences OCD symptom presentation, interpretation of intrusive thoughts, and treatment-seeking behavior, necessitating culturally adapted therapeutic approaches. Religious and moral obsessions, for instance, manifest differently across faith traditions, with content reflecting culturally specific concerns about sin, spiritual contamination, or ritual purity. Muslim patients may experience scrupulosity regarding prayer rituals and ablution, while Christian patients often report blasphemous thoughts or concerns about eternal damnation. Hindu patients might focus on purity concerns related to caste or ritual practices. Therapists must develop cultural competence regarding religious traditions to effectively differentiate normative religious practice from pathological obsessive-compulsive symptoms (Huppert & Siev, 2010).

Stigma surrounding mental illness varies considerably across cultural contexts, affecting disclosure of symptoms, willingness to engage treatment, and family involvement in care. Some Asian and Latino cultures emphasize family harmony and may view individual psychotherapy as threatening family cohesion or bringing shame to the family unit. For these populations, family-inclusive treatment approaches that position therapy as benefiting the entire family system may enhance engagement and outcomes. Language barriers require attention when working with non-native English speakers, as nuanced assessment of obsessional content and cognitive appraisals demands linguistic precision. Use of professional interpreters and validated translated assessment instruments improves diagnostic accuracy and therapeutic alliance.

Cultural adaptations of evidence-based treatments have demonstrated feasibility and effectiveness across diverse populations. Adapted protocols maintain core therapeutic elements while modifying examples, metaphors, homework assignments, and treatment framing to align with cultural values and worldviews. For example, ACT protocols adapted for Muslim populations incorporate Islamic concepts of acceptance and values clarification while maintaining the evidence-based structure of treatment. Research examining culturally adapted interventions generally demonstrates outcomes equivalent or superior to standard protocols, with enhanced treatment retention and patient satisfaction (Laird et al., 2019). Ongoing research continues to refine our understanding of cultural variables moderating treatment response and optimal adaptation strategies.

Treatment Challenges and Complications

Poor insight represents a significant predictor of treatment complications and poorer outcomes, with approximately 30% of individuals with OCD demonstrating overvalued ideation or delusional conviction regarding their obsessional beliefs. Patients with poor insight show reluctance to engage exposure exercises, challenge cognitive distortions, or recognize compulsions as excessive, substantially compromising treatment effectiveness. Specialized interventions for poor insight include motivational interviewing techniques, inferential confusion approaches, and careful scaffolding of behavioral experiments that may gradually shift conviction in obsessional beliefs. Augmentation with antipsychotic medications may prove beneficial for this subgroup (Eisen et al., 2010).

Treatment-resistant OCD, typically defined as failure to respond adequately to multiple trials of evidence-based treatments, affects an estimated 10-20% of individuals with the disorder. Evaluation of treatment resistance requires careful consideration of whether prior treatments represented adequate trials—appropriate dose, duration, therapist competence, and patient adherence. Reassessment may reveal previously undetected factors maintaining symptoms, including unrecognized compulsions, safety behaviors, family accommodation, or comorbid conditions. Stepped-care approaches for treatment-resistant cases may include intensive or residential treatment, medication algorithm optimization, neurostimulation interventions such as transcranial magnetic stimulation, or deep brain stimulation for the most severe, refractory presentations.

Comorbidity represents the rule rather than exception in OCD, with approximately 75% of individuals meeting criteria for at least one additional psychiatric disorder during their lifetime. Major depressive disorder, other anxiety disorders, attention-deficit/hyperactivity disorder, tic disorders, and personality disorders commonly co-occur with OCD, each complicating treatment in distinct ways. Severe depression may impair motivation and energy necessary for exposure exercises, requiring concurrent depression treatment or medication to facilitate engagement with OCD-focused therapy. Comorbid personality disorders, particularly obsessive-compulsive personality disorder (which is distinct from OCD despite similar nomenclature), may require integrated treatment addressing pervasive patterns of perfectionism, rigidity, and interpersonal difficulties alongside obsessive-compulsive symptoms.

Relapse Prevention and Long-Term Outcomes

Relapse prevention planning represents a critical component of OCD treatment, as symptom recurrence following treatment discontinuation affects approximately 25-40% of individuals within two years. Effective relapse prevention involves identifying personal warning signs of symptom return, developing action plans for implementing learned coping strategies at early recurrence, and planning for booster sessions when needed. Patients benefit from understanding that occasional intrusive thoughts and anxiety represent normal experiences rather than indicators of treatment failure, with the key distinction being whether they respond with compulsive behaviors or acceptance and values-based action (Hiss et al., 1994).

Medication discontinuation requires careful planning, as abrupt cessation of SSRIs may precipitate withdrawal symptoms and symptom return. When patients achieve sustained remission with combined treatment, collaborative decision-making regarding medication taper versus maintenance proves essential. Research suggests that individuals who receive adequate cognitive-behavioral therapy demonstrate better maintenance of gains following medication discontinuation compared to those treated with medication alone, supporting the importance of including psychotherapy in comprehensive treatment plans. For some individuals, long-term maintenance medication provides optimal outcomes, particularly those with early onset, severe symptoms, or multiple prior relapses.

Long-term outcome research demonstrates that most individuals who receive evidence-based treatment experience substantial and durable improvement in symptoms and functioning. Prospective studies following patients for five years or longer after treatment show that approximately 50-60% maintain clinically significant gains, with another 25-30% experiencing partial improvement. Predictors of favorable long-term outcomes include good treatment response, completion of full treatment protocols, regular implementation of learned strategies, minimal family accommodation, and absence of severe comorbidity. Ongoing research examining methods to enhance long-term maintenance of therapeutic gains remains a priority, with approaches including scheduled booster sessions, mindfulness-based relapse prevention, and peer support interventions showing preliminary promise.

Emerging Treatments and Future Directions

Novel neuromodulation approaches including transcranial magnetic stimulation and deep brain stimulation represent emerging interventions for severe, treatment-refractory OCD. Repetitive transcranial magnetic stimulation targets specific brain regions implicated in OCD pathophysiology, particularly the supplementary motor area and orbitofrontal cortex, with meta-analytic evidence suggesting modest efficacy as an augmentation strategy for treatment-resistant cases (Trevizol et al., 2016). Deep brain stimulation, involving surgical implantation of electrodes in specific neural circuits, received approval for humanitarian use in severe, treatment-refractory OCD in 2009, with research demonstrating clinically significant improvement in approximately 50% of carefully selected candidates.

Neurobiological research elucidating the neural circuits and neurotransmitter systems involved in OCD continues to inform treatment development. Findings implicating dysfunction in cortico-striato-thalamo-cortical circuits, particularly involving the orbitofrontal cortex, anterior cingulate cortex, and striatum, have led to circuit-based treatment approaches. Research examining glutamatergic dysfunction has sparked interest in glutamate-modulating medications such as d-cycloserine, memantine, and riluzole as potential augmentation strategies. While results have been mixed, this line of investigation represents a promising direction for pharmacological innovation beyond traditional serotonergic approaches (Pittenger et al., 2015).

Personalized medicine approaches seek to identify biological and psychological markers predicting differential treatment response, enabling precision matching of individuals to optimal interventions. Research examining genetic polymorphisms, neuroimaging markers, cognitive profiles, and symptom dimensions as predictors of treatment response remains in early stages but holds substantial promise. Machine learning algorithms analyzing complex combinations of clinical, demographic, and biological variables may eventually enable accurate prediction of which individuals will respond best to medication versus psychotherapy, ERP versus ACT, or standard versus intensive treatment formats. Such advances could substantially reduce the trial-and-error approach currently characterizing much of clinical practice.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

American Psychological Association. (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. https://www.apa.org/practice/guidelines/ocd

Andersson, E., Enander, J., Andrén, P., Hedman, E., Ljótsson, B., Hursti, T., Bergström, J., Kaldo, V., Lindefors, N., Andersson, G., & Rück, C. (2012). Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: A randomised controlled trial. Psychological Medicine, 42(10), 2193-2203. https://doi.org/10.1017/S0033291712000244

Bloch, M. H., Landeros-Weisenberger, A., Rosario, M. C., Pittenger, C., & Leckman, J. F. (2008). Meta-analysis of the symptom structure of obsessive-compulsive disorder. American Journal of Psychiatry, 165(12), 1532-1542. https://doi.org/10.1176/appi.ajp.2008.08020320

Eisen, J. L., Rasmussen, S. A., Phillips, K. A., Price, L. H., Davidson, J., Lydiard, R. B., Ninan, P., & Piggott, T. (2010). Insight and treatment outcome in obsessive-compulsive disorder. Comprehensive Psychiatry, 42(6), 494-497. https://doi.org/10.1053/comp.2001.27898

Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., Simpson, H. B., & Tu, X. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162(1), 151-161. https://doi.org/10.1176/appi.ajp.162.1.151

Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., Heninger, G. R., & Charney, D. S. (1989). The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Archives of General Psychiatry, 46(11), 1006-1011. https://doi.org/10.1001/archpsyc.1989.01810110048007

Hiss, H., Foa, E. B., & Kozak, M. J. (1994). Relapse prevention program for treatment of obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology, 62(4), 801-808. https://doi.org/10.1037/0022-006X.62.4.801

Huppert, J. D., & Siev, J. (2010). Treating scrupulosity in religious individuals using cognitive-behavioral therapy. Cognitive and Behavioral Practice, 17(4), 382-392. https://doi.org/10.1016/j.cbpra.2009.07.003

Kim, K., Kim, C. H., Cha, K. R., Park, J., Han, K., Kim, Y. K., Kim, J. J., Kim, I. Y., & Kim, S. I. (2008). Virtual reality for obsessive-compulsive disorder: Past and the future. Psychiatry Investigation, 5(2), 115-121. https://doi.org/10.4306/pi.2008.5.2.115

Laird, K. T., Krause, K., Funes, C., & Lavretsky, H. (2019). Psychobiological factors of resilience and depression in late life. Translational Psychiatry, 9(1), 88. https://doi.org/10.1038/s41398-019-0424-7

O’Connor, K., Aardema, F., & Pélissier, M. C. (2005). Beyond reasonable doubt: Reasoning processes in obsessive-compulsive disorder and related disorders. John Wiley & Sons. https://doi.org/10.1002/9780470713242

Obsessive Compulsive Cognitions Working Group. (2005). Psychometric validation of the obsessive belief questionnaire and interpretation of intrusions inventory—Part 2: Factor analyses and testing of a brief version. Behaviour Research and Therapy, 43(11), 1527-1542. https://doi.org/10.1016/j.brat.2004.07.010

Oldfield, V. B., Salkovskis, P. M., & Taylor, T. (2011). Time-intensive cognitive behaviour therapy for obsessive-compulsive disorder: A case series and matched comparison group. British Journal of Clinical Psychology, 50(1), 7-18. https://doi.org/10.1348/014466510X490041

Olatunji, B. O., Davis, M. L., Powers, M. B., & Smits, J. A. (2013). Cognitive-behavioral therapy for obsessive-compulsive disorder: A meta-analysis of treatment outcome and moderators. Journal of Psychiatric Research, 47(1), 33-41. https://doi.org/10.1016/j.jpsychires.2012.08.020

Piacentini, J., Bergman, R. L., Chang, S., Langley, A., Peris, T., Wood, J. J., & McCracken, J. (2011). Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 50(11), 1149-1161. https://doi.org/10.1016/j.jaac.2011.08.003

Pittenger, C., Bloch, M. H., & Williams, K. (2015). Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics, 132(3), 314-332. https://doi.org/10.1016/j.pharmthera.2011.09.006

Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., & Marín-Martínez, F. (2008). Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clinical Psychology Review, 28(8), 1310-1325. https://doi.org/10.1016/j.cpr.2008.07.001

Salkovskis, P. M. (1985). Obsessional-compulsive problems: A cognitive-behavioural analysis. Behaviour Research and Therapy, 23(5), 571-583. https://doi.org/10.1016/0005-7967(85)90105-6

Simpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., Campeas, R., Hahn, C. G., & Petkova, E. (2008). A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. American Journal of Psychiatry, 165(5), 621-630. https://doi.org/10.1176/appi.ajp.2007.07091440

Soomro, G. M., Altman, D., Rajagopal, S., & Oakley-Browne, M. (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews, 1, CD001765. https://doi.org/10.1002/14651858.CD001765.pub3

Trevizol, A. P., Shiozawa, P., Cook, I. A., Sato, I. A., Kaku, C. B., Guimarães, F. B., Sachdev, P., Sarkhel, S., & Cordeiro, Q. (2016). Transcranial magnetic stimulation for obsessive-compulsive disorder: An updated systematic review and meta-analysis. The Journal of ECT, 32(4), 262-266. https://doi.org/10.1097/YCT.0000000000000335